| Acute untreated | Acute treated | P valued |
---|---|---|---|
Number of participants | 12 | 8 | Â |
Female, N (%) | 12 (100%) | 8 (100%) | > 0.999 |
Age in years | 21 (21–24) | 22 (20–23) | 0.917 |
Fiebig stages I–II at diagnosis, N (%)a | 11 (92%) | 8 (100%) | > 0.999 |
Fiebig stages I–II at ART initiation, N (%) | N/A | 8 (100%) | N/A |
Days from detection to ART initiation and range | N/A | 1 (1–2) | N/A |
Nadir CD4+ T cell countsb (cells/μL) | 329 (233–458) | 840 (623–1008) | < 0.001 |
Peak viral load (log10 RNA copies/mL) | 7.08 (6.93–7.75) | 4.26 (3.45–5.13) | < 0.001 |
Days from detection to viral suppression and range | N/A | 23 (7–63) | N/A |
Set point CD4+ T cell counts (cells/μL)c | 583 (555–630) | N/A | N/A |
Set point viral load (log10 RNA copies/mL)c | 4.74 (4.11–5.36) | N/A | N/A |